REGENXBIO Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $108.0M | $6.4M | $30.3M | $29.7M | $21.4M | $89.0M | $21.2M | $24.2M |
| Cost of Revenue | — | — | — | — | — | — | $6.3M | $12.4M |
| Gross Profit | — | — | — | — | — | — | $14.9M | $11.8M |
| Gross Margin | — | — | — | — | — | — | 70.2% | 48.8% |
| Operating Expenses | ||||||||
| Research & Development | $56.1M | $57.3M | $59.6M | $56.1M | $59.5M | $53.1M | $50.4M | $54.4M |
| SG&A Expense | $21.6M | $21.3M | $22.4M | $20.3M | $19.9M | $20.3M | $20.1M | $19.4M |
| Operating Income | $29.3M | $-83.4M | $-57.6M | $-52.4M | $-63.3M | $12.1M | $-51.4M | $-62.1M |
| Operating Margin | 27.1% | -1,304.0% | -190.0% | -176.3% | -296.3% | 13.6% | -242.1% | -256.6% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $22.7M | $-90.1M | $-67.1M | $-61.9M | $-70.9M | $6.1M | $-51.2M | $-59.6M |
| Net Margin | 21.0% | -1,408.6% | -221.3% | -208.3% | -331.8% | 6.8% | -241.3% | -246.3% |
| EPS (Basic) | $0.43 | $-1.72 | $-1.30 | $-1.20 | $-1.38 | $0.12 | $-0.99 | $-1.17 |
| EPS (Diluted) | $0.43 | $-1.72 | $-1.30 | $-1.20 | $-1.38 | $0.12 | $-0.99 | $-1.17 |
| Shares Outstanding (Basic) | 52.8M | 52.4M | 51.6M | 51.7M | 51.5M | 51.4M | 49.5M | 50.8M |
| Shares Outstanding (Diluted) | 53.0M | 52.4M | 51.6M | 51.7M | 51.5M | 51.4M | 49.5M | 50.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |